# DYNC1H1

## Overview
The DYNC1H1 gene encodes the dynein cytoplasmic 1 heavy chain 1 protein, a pivotal component of the cytoplasmic dynein motor complex. This protein is categorized as a motor protein and plays a crucial role in intracellular transport processes, particularly retrograde transport along microtubules. The dynein cytoplasmic 1 heavy chain 1 protein is essential for various cellular functions, including vesicular trafficking, organelle positioning, and nuclear movement, which are vital for maintaining cellular integrity and function (ReckPeterson2018The; Dahl2021Effect). Mutations in the DYNC1H1 gene are linked to several neuromuscular and neurodevelopmental disorders, underscoring its importance in neuronal development and survival (Das2018A; Ge2023Case).

## Structure
The DYNC1H1 gene encodes the dynein cytoplasmic 1 heavy chain 1 protein, a critical component of the cytoplasmic dynein complex involved in intracellular transport. The protein is a large polypeptide chain consisting of 4,634 amino acids, forming a complex structure with distinct domains (ReckPeterson2018The). The primary structure of DYNC1H1 includes a long sequence of amino acids, while its secondary structure is characterized by alpha helices and beta sheets (Canty2020Activation).

The tertiary structure of DYNC1H1 features a motor domain with ATPase activity, essential for its function in cellular motility. This motor domain contains a ring of six AAA+ domains, with AAA1 being the primary site for ATP hydrolysis, which drives the protein's movement along microtubules (Cianfrocco2015Mechanism). The quaternary structure involves the interaction of the dynein heavy chain with other subunits, forming a homodimer that is crucial for its function (Canty2020Activation).

Key domains of the DYNC1H1 protein include the C-terminal motor domain and the N-terminal tail domain, which is involved in dimerization and cargo binding. The microtubule-binding domain (MTBD) is located at the end of a coiled-coil stalk, which extends from the AAA+ ring (ReckPeterson2018The). The protein may undergo post-translational modifications such as phosphorylation, although specific details are not provided in the context. Splice variant isoforms of DYNC1H1 may exist, potentially leading to proteins with distinct functions (Canty2020Activation).

## Function
The DYNC1H1 gene encodes the heavy chain of cytoplasmic dynein, a major motor protein complex in eukaryotic cells. This complex is essential for retrograde transport along microtubules, moving cellular components towards the minus end of microtubules. In healthy human cells, DYNC1H1 plays a crucial role in various cellular processes, including vesicular trafficking, organelle positioning, and nuclear movement (Dahl2021Effect). The motor domain of DYNC1H1 couples ATP hydrolysis with a mechanochemical cycle to facilitate movement, which is vital for the proper functioning of photoreceptor cells, among other cell types (Dahl2021Effect).

DYNC1H1 is prominently expressed in the inner segments, outer plexiform layer, and inner plexiform layer of the retina, where it is involved in the transport of membrane proteins such as rhodopsin from the rough endoplasmic reticulum to the Golgi apparatus and subsequently to the outer segments of photoreceptors (Dahl2021Effect). This transport is critical for maintaining the structural integrity and function of photoreceptors by ensuring proper protein trafficking and nuclear positioning. The absence of functional DYNC1H1 leads to disorganization of nuclear layers and impaired ciliogenesis, highlighting its importance in neurogenesis and neuronal survival (Dahl2021Effect).

## Clinical Significance
Mutations in the DYNC1H1 gene are associated with a range of neuromuscular and neurodevelopmental disorders. One of the primary conditions linked to these mutations is Spinal Muscular Atrophy with Lower Extremity Predominance (SMALED), an autosomal dominant variant of spinal muscular atrophy that primarily affects the lower extremities. Clinical features of SMALED include congenital hip displacement, talipes, delayed motor development, and lower limb weakness, with relative sparing of the upper extremities (Tsurusaki2012A; Das2018A).

DYNC1H1 mutations are also implicated in Charcot-Marie-Tooth disease type 2O (CMT2O), a hereditary motor and sensory neuropathy characterized by progressive distal muscle weakness and wasting, sometimes accompanied by sensory abnormalities (Li2022Expanding). Additionally, these mutations can lead to malformations of cortical development (MCD), intellectual disabilities, and epilepsy, particularly when associated with pachygyria, a type of MCD (Ge2023Case).

The gene's mutations have pleiotropic effects, meaning the same mutation can cause different disorders, such as both spinal muscular atrophy and distal neuropathy (Tsurusaki2012A). The clinical manifestations of DYNC1H1-related disorders vary widely, reflecting the gene's critical role in neuronal function and development (Becker2020The).

## Interactions
The DYNC1H1 gene encodes a protein that is a core component of the cytoplasmic dynein motor complex, which is crucial for retrograde transport along microtubules. This complex is essential for neuron development, morphology, and survival due to the reliance of neurons on the microtubule transport system (Beecroft2017Expanding). DYNC1H1 interacts with intermediate-light and light dynein chains to form a cargo-binding complex, and its long tail domain at the N-terminus contains the dimerization domain (Beecroft2017Expanding). The protein also interacts with BICD2, an adaptor protein that links various cellular cargos to the dynein-dynactin motor complex (Beecroft2017Expanding). 

DYNC1H1 is involved in interactions that are crucial for its function in motor neuron diseases. Pathogenic variants in DYNC1H1 affect the interaction between dynein-1, dynactin, and cargo adaptor complexes, which can lead to neurological disorders (Mentis2021A). The protein also interacts with dynein axonemal assembly factors, which are implicated in ALS pathophysiology (Mentis2021A). The DYNC1H1 protein structure includes specific domains such as the coiled coil domain, ATPase domain, and microtubule-binding domain, with interactions involving DYNC1I2 and DYNC1LI2 at the protein level (Becker2020The).


## References


[1. (Beecroft2017Expanding) Sarah J. Beecroft, Catriona A. McLean, Martin B. Delatycki, Kurian Koshy, Eppie Yiu, Goknur Haliloglu, Diclehan Orhan, Phillipa J. Lamont, Mark R. Davis, Nigel G. Laing, and Gianina Ravenscroft. Expanding the phenotypic spectrum associated with mutations of dync1h1. Neuromuscular Disorders, 27(7):607–615, July 2017. URL: http://dx.doi.org/10.1016/j.nmd.2017.04.011, doi:10.1016/j.nmd.2017.04.011. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.nmd.2017.04.011)

[2. (Mentis2021A) Alexios-Fotios Mentis, Dimitrios Vlachakis, Eleni Papakonstantinou, Ioannis Zaganas, George P. Patrinos, George P. Chrousos, and Efthimios Dardiotis. A novel variant in dync1h1 could contribute to human amyotrophic lateral sclerosis-frontotemporal dementia spectrum. Molecular Case Studies, pages mcs.a006096, September 2021. URL: http://dx.doi.org/10.1101/mcs.a006096, doi:10.1101/mcs.a006096. This article has 7 citations.](https://doi.org/10.1101/mcs.a006096)

[3. (ReckPeterson2018The) Samara L. Reck-Peterson, William B. Redwine, Ronald D. Vale, and Andrew P. Carter. The cytoplasmic dynein transport machinery and its many cargoes. Nature Reviews Molecular Cell Biology, 19(6):382–398, April 2018. URL: http://dx.doi.org/10.1038/s41580-018-0004-3, doi:10.1038/s41580-018-0004-3. This article has 506 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41580-018-0004-3)

[4. (Dahl2021Effect) Tiffanie M. Dahl, Michelle Reed, Cecilia D. Gerstner, Guoxin Ying, and Wolfgang Baehr. Effect of conditional deletion of cytoplasmic dynein heavy chain dync1h1 on postnatal photoreceptors. PLOS ONE, 16(3):e0248354, March 2021. URL: http://dx.doi.org/10.1371/journal.pone.0248354, doi:10.1371/journal.pone.0248354. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0248354)

[5. (Becker2020The) Lena-Luise Becker, Hormos Salimi Dafsari, Jens Schallner, Dalia Abdin, Michael Seifert, Florence Petit, Thomas Smol, Levinus Bok, Lance Rodan, Ingrid Krapels, Stephanie Spranger, Bernhard Weschke, Katherine Johnson, Volker Straub, Angela M. Kaindl, Nataliya Di Donato, Maja von der Hagen, and Sebahattin Cirak. The clinical-phenotype continuum in dync1h1-related disorders—genomic profiling and proposal for a novel classification. Journal of Human Genetics, 65(11):1003–1017, August 2020. URL: http://dx.doi.org/10.1038/s10038-020-0803-1, doi:10.1038/s10038-020-0803-1. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s10038-020-0803-1)

[6. (Canty2020Activation) John T. Canty and Ahmet Yildiz. Activation and regulation of cytoplasmic dynein. Trends in Biochemical Sciences, 45(5):440–453, May 2020. URL: http://dx.doi.org/10.1016/j.tibs.2020.02.002, doi:10.1016/j.tibs.2020.02.002. This article has 59 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.tibs.2020.02.002)

[7. (Li2022Expanding) Jia-Tong Li, Si-Qi Dong, Dong-Qing Zhu, Wen-Bo Yang, Ting Qian, Xiao-Ni Liu, and Xiang-Jun Chen. Expanding the phenotypic and genetic spectrum of neuromuscular diseases caused by dync1h1 mutations. Frontiers in Neurology, July 2022. URL: http://dx.doi.org/10.3389/fneur.2022.943324, doi:10.3389/fneur.2022.943324. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fneur.2022.943324)

[8. (Cianfrocco2015Mechanism) Michael A. Cianfrocco, Morgan E. DeSantis, Andres E. Leschziner, and Samara L. Reck-Peterson. Mechanism and regulation of cytoplasmic dynein. Annual Review of Cell and Developmental Biology, 31(1):83–108, November 2015. URL: http://dx.doi.org/10.1146/annurev-cellbio-100814-125438, doi:10.1146/annurev-cellbio-100814-125438. This article has 209 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1146/annurev-cellbio-100814-125438)

[9. (Tsurusaki2012A) Yoshinori Tsurusaki, Shinji Saitoh, Kazuhiro Tomizawa, Akira Sudo, Naoko Asahina, Hideaki Shiraishi, Jun-ichi Ito, Hajime Tanaka, Hiroshi Doi, Hirotomo Saitsu, Noriko Miyake, and Naomichi Matsumoto. A dync1h1 mutation causes a dominant spinal muscular atrophy with lower extremity predominance. neurogenetics, 13(4):327–332, July 2012. URL: http://dx.doi.org/10.1007/s10048-012-0337-6, doi:10.1007/s10048-012-0337-6. This article has 60 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10048-012-0337-6)

[10. (Das2018A) Joyutpal Das, James B. Lilleker, Kavaldeep Jabbal, and John Ealing. A missense mutation in dync1h1 gene causing spinal muscular atrophy – lower extremity, dominant. Neurologia i Neurochirurgia Polska, 52(2):293–297, March 2018. URL: http://dx.doi.org/10.1016/j.pjnns.2017.12.004, doi:10.1016/j.pjnns.2017.12.004. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.pjnns.2017.12.004)

[11. (Ge2023Case) Wen-Rong Ge, Pei-Pei Fu, Wei-Na Zhang, Bo Zhang, Ying-Xue Ding, and Guang Yang. Case report: genotype and phenotype of dync1h1-related malformations of cortical development: a case report and literature review. Frontiers in Neurology, April 2023. URL: http://dx.doi.org/10.3389/fneur.2023.1163803, doi:10.3389/fneur.2023.1163803. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fneur.2023.1163803)